CCIA
OREX

Campbell & Co Investment Adviser’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7,801
Closed -$478K – 388
2013
Q3 		$478K Buy
+7,801
New +$528K 0.09% 173

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Campbell & Co Investment Adviser's OREX Position: Q4 2013 in Review

Campbell & Co Investment Adviser sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 7,801 shares — an estimated $478K sold.

Campbell & Co Investment Adviser first reported a position in OREX in Q3 2013 and held it in 1 quarter. The position peaked at $478K in Q3 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • Campbell & Co Investment Adviser reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 7,801 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $478K.
  • Campbell & Co Investment Adviser first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Orexigen Therapeutics, Inc. position peaked at $478K in Q3 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2013, filed 6 Feb 2014.